Cargando…

Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children

BACKGROUND: Owing to insufficient evidence in children, target plasma concentrations of efavirenz are based on studies in adults. Our analysis aimed to evaluate the pediatric therapeutic thresholds and characterize the determinants of virological suppression in African children. METHODS: We analyzed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bienczak, Andrzej, Denti, Paolo, Cook, Adrian, Wiesner, Lubbe, Mulenga, Veronica, Kityo, Cissy, Kekitiinwa, Addy, Gibb, Diana M., Burger, David, Walker, A. Sarah, McIlleron, Helen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	JAIDS Journal of Acquired Immune Deficiency Syndromes 2016
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5172513/ https://www.ncbi.nlm.nih.gov/pubmed/27116047 http://dx.doi.org/10.1097/QAI.0000000000001032

Ejemplares similares

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children
por: Bienczak, Andrzej, et al.
Publicado: (2016)

Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children
por: Bienczak, Andrzej, et al.
Publicado: (2017)

Evaluation of an immunoassay for determination of plasma efavirenz concentrations in resource-limited settings
por: Abdissa, Alemseged, et al.
Publicado: (2014)

Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial
por: Mulenga, Veronica, et al.
Publicado: (2016)

HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients
por: Rockwood, Neesha, et al.
Publicado: (2016)

Correlation of hair and plasma efavirenz concentrations in HIV-positive South Africans
por: Johnston, Jenna, et al.
Publicado: (2019)

First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial
por: Waalewijn, Hylke, et al.
Publicado: (2023)

Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment
por: Shiau, Stephanie, et al.
Publicado: (2014)

Bedaquiline exposure in pregnancy and breastfeeding in women with rifampicin‐resistant tuberculosis
por: Court, Richard, et al.
Publicado: (2022)

Abacavir pharmacokinetics in African children living with HIV: A pooled analysis describing the effects of age, malnutrition and common concomitant medications
por: Tikiso, Tjokosela, et al.
Publicado: (2021)

Population pharmacokinetics of ethambutol in African children: a pooled analysis
por: Tikiso, Tjokosela, et al.
Publicado: (2022)

Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy
por: Naiker, Suhashni, et al.
Publicado: (2014)

Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations
por: Sinxadi, Phumla Zuleika, et al.
Publicado: (2016)

Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis
por: Court, Richard, et al.
Publicado: (2021)

Concentration-Response Relationships of Dolutegravir and Efavirenz with Weight Change After Starting Antiretroviral Therapy
por: Griesel, Rulan, et al.
Publicado: (2022)

Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis
por: Ngwalero, Precious, et al.
Publicado: (2021)

Mortality in the Year Following Antiretroviral Therapy Initiation in HIV-Infected Adults and Children in Uganda and Zimbabwe
por: Walker, A. Sarah, et al.
Publicado: (2012)

Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus‐associated tuberculosis
por: Schutz, Charlotte, et al.
Publicado: (2020)

Severe efavirenz associated neurotoxicity: A retrospective cohort study
por: Arnab, Priyadarshini, et al.
Publicado: (2023)

An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3′-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients
por: Swart, Marelize, et al.
Publicado: (2016)

Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir
por: Moultrie, Harry, et al.
Publicado: (2015)

Pharmacokinetics and Drug-Drug Interactions of Abacavir and Lamuvudine Co-administered With Antituberculosis Drugs in HIV-Positive Children Treated for Multidrug-Resistant Tuberculosis
por: van der Laan, Louvina E., et al.
Publicado: (2021)

Pharmacokinetics of antitubercular drugs in patients hospitalized with HIV-associated tuberculosis: a population modeling analysis
por: Abdelgawad, Noha, et al.
Publicado: (2022)

Excellent Adherence to Antiretrovirals in HIV+ Zambian Children Is Compromised by Disrupted Routine, HIV Nondisclosure, and Paradoxical Income Effects
por: Haberer, Jessica E., et al.
Publicado: (2011)

Improved Adherence to Antiretroviral Therapy Observed Among HIV-Infected Children Whose Caregivers had Positive Beliefs in Medicine in Sub-Saharan Africa
por: Abongomera, G., et al.
Publicado: (2016)

Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults
por: Lamorde, Mohammed, et al.
Publicado: (2012)

Inadequate Lopinavir Concentrations With Modified 8-Hourly Lopinavir/Ritonavir 4:1 Dosing During Rifampicin-based Tuberculosis Treatment in Children Living With HIV
por: Chabala, Chishala, et al.
Publicado: (2023)

Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children
por: Zhang, C, et al.
Publicado: (2010)

Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania
por: Denti, Paolo, et al.
Publicado: (2015)

Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization–Recommended Weight Band Doses and Formulations
por: Chabala, Chishala, et al.
Publicado: (2021)

A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine
por: Francis, Jose, et al.
Publicado: (2019)

The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa
por: Shearer, Kate, et al.
Publicado: (2014)

Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship
por: Bhatt, Nilesh B., et al.
Publicado: (2015)

Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy
por: Svensson, Elin M., et al.
Publicado: (2017)

Impact of second-line antiretroviral regimens on lipid profiles in an African setting: the DART trial sub-study
por: Gomo, Zvenyika AR, et al.
Publicado: (2014)

Poor Penetration of Antibiotics Into Pericardium in Pericardial Tuberculosis
por: Shenje, Justin, et al.
Publicado: (2015)

Quality assurance of rifampicin-containing fixed-drug combinations in South Africa: dosing implications
por: Court, R., et al.
Publicado: (2018)

Current research toward optimizing dosing of first-line antituberculosis treatment
por: McIlleron, Helen, et al.
Publicado: (2018)

Long-term virological suppression on first-line efavirenz + tenofovir + emtricitabine/lamivudine for HIV-1
Publicado: (2019)

The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study
por: De Nicolò, Amedeo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4idu8uadvg9piqk41dshari45d